Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
2,018.00    12.00 (0.60%)
Bid:
2,026.00
Ask:
2,028.00
Spread: 2.00 (0.099%)
Market Cap: £2.24b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

DISPOSAL OF JOHNSON BUILDING

3 Dec 2020 07:00

RNS Number : 3529H
Derwent London PLC
03 December 2020
Β 

Derwent London plc ("Derwent London" / "the Group")DISPOSAL OF JOHNSON BUILDING

Β 

Β 

Derwent London announces that it has exchanged contracts to sell its 192,700 sq ft freehold interest in Johnson Building, 77 Hatton Garden and 5-7 St Cross Street EC1 to Eurazeo Patrimoine, the real assets division of Eurazeo. The headline price is Β£170m before rental top-ups of Β£2.4m for incentives and vacant space.

Β 

The office and retail complex was acquired in 2000 for Β£29m, and in 2006 the Group completed a significant refurbishment designed by architects AHMM which increased the lettable area by 53%.

Β 

The total rent passing from the multi-let buildings is Β£7.3m pa with approximately 40% of the income expiring in 2021.

Β 

The sale price represents a net initial yield of 4.1% on the passing rent, which will fall to 2.5% allowing for 2021 lease expiries. The disposal price, net of incentives, is 4% below the June 2020 book value before costs. This crystallises an IRR of 10% pa to the Group since acquisition.

Β 

Paul Williams, Chief Executive of Derwent London, said:

"The refurbishment of the Johnson Building was one of our first generation of schemes and the sale continues our strategy of disposing of mature assets. The proceeds will be reinvested into new developments with superior growth prospects, such as 19-35 Baker Street W1 which is scheduled to start on site in 2021."

Β 

Β 

For further information, please contact:

Β 

Derwent London

Tel: +44 (0)20 7659 3000

Β 

Paul Williams, Chief Executive

David Silverman, Executive Director

Quentin Freeman, Head of Investor Relations

Β 

Brunswick Group

Tel: +44 (0)20 7404 5959

Β 

Β 

Nina Coad

Emily Trapnell

Β 

Β 

Notes to editors

Β 

Β 

Derwent London plc

Β 

Derwent London plc owns 83 buildings in a commercial real estate portfolio predominantly in central London valued at Β£5.4 billion (including joint ventures) as at 30 June 2020, making it the largest London-focused real estate investment trust (REIT).

Β 

Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via development or refurbishment, effective asset management and capital recycling.

Β 

We typically acquire central London properties off-market with low capital values and modest rents in improving locations, most of which are either in the West End or the Tech Belt. We capitalise on the unique qualities of each of our properties - taking a fresh approach to the regeneration of every building with a focus on anticipating tenant requirements and an emphasis on design.

Β 

Reflecting and supporting our long-term success, the business has a strong balance sheet with modest leverage, a robust income stream and flexible financing.

Β 

As part of our commitment to lead the industry in mitigating climate change, in October 2019, Derwent London became the first UK REIT to sign a Green Revolving Credit Facility. At the same time, we also launched our Green Finance Framework and signed the Better Buildings Partnership's climate change commitment. The Group is a member of the 'RE100' which recognises Derwent London as an influential company, committed to 100% renewable power by purchasing renewable energy, a key step in becoming a net zero carbon business. Derwent London is one of only a few property companies worldwide to have science-based carbon targets validated by the Science Based Targets initiative (SBTi).

Β 

Landmark schemes in our 5.6 million sq ft portfolio include 80 Charlotte Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1, 1-2 Stephen Street W1, Horseferry House SW1 and Tea Building E1.

Β 

In 2020 the Group has won several awards for Brunel Building with the most prominent being the BCO Best Commercial Workplace award. In 2019 the Group won EG Offices Company of the Year, the CoStar West End Deal of the Year for Brunel Building, Westminster Business Council's Best Achievement in Sustainability award and topped the real estate sector and was placed ninth overall in the Management Today 2019 awards for 'Britain's Most Admired Companies'. In 2013 the Company launched a voluntary Community Fund and has to date supported over 100 community projects in the West End and the Tech Belt.

Β 

The Company is a public limited company, which is listed on the London Stock Exchange and incorporated and domiciled in the UK. The address of its registered office is 25 Savile Row, London, W1S 2ER.

Β 

For further information see www.derwentlondon.com or follow us on Twitter at @derwentlondon

Β 

Β 

About Eurazeo

Eurazeo is a leading global investment company, with a diversified portfolio of €18.8 billion in assets under management, including €13.3 billion from third parties, invested in over 430 companies. With its considerable private equity, real estate and private debt expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 300 professionals and by offering in-depth sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, Singapore, London, Luxembourg, Frankfurt, Berlin and Madrid.

Eurazeo is listed on Euronext Paris.

ISIN: FR0000121121 - Bloomberg: RF FP - Reuters: EURA.PA

Β 

Forward-looking statements

This document contains certain forward-looking statements about the future outlook of Derwent London. By their nature, any statements about future outlook involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. Actual results, performance or outcomes may differ materially from any results, performance or outcomes expressed or implied by such forward-looking statements.

No representation or warranty is given in relation to any forward-looking statements made by Derwent London, including as to their completeness or accuracy. Derwent London does not undertake to update any forward-looking statements whether as a result of new information, future events or otherwise. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DISMZMGZGZMGGZZ
Date   Source Headline
6th Jul 20267:00 amRNSTransaction in Own Shares
3rd Jul 202612:15 pmRNSHolding(s) in Company
1st Jul 20267:00 amRNSHorseferry House and 80-85 Tottenham Court Road
30th Jun 20265:15 pmRNSTotal Voting Rights
29th Jun 20267:00 amRNSTransaction in Own Shares
23rd Jun 202611:30 amRNSHolding(s) in Company
22nd Jun 20267:00 amRNSTransaction in Own Shares
15th Jun 20267:00 amRNSTransaction in Own Shares
11th Jun 20267:00 amRNSDirectorate change
8th Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20262:00 pmRNSHolding(s) in Company
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:37 pmRNSTotal Voting Rights
26th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:15 pmRNSDirector/PDMR Shareholding
19th May 202610:00 amRNSDirector Declaration
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202611:45 amRNSResult of AGM
12th May 20267:00 amRNSTrading Statement
1st May 202610:30 amRNSHolding(s) in Company
30th Apr 20264:45 pmRNSTotal Voting Rights
22nd Apr 20265:00 pmRNSHolding(s) in Company
22nd Apr 202610:15 amRNSHolding(s) in Company
20th Apr 202610:30 amRNSHolding(s) in Company
14th Apr 202611:14 amRNSAnnual Financial Report
10th Apr 20264:45 pmRNSAdmission to Trading
7th Apr 20265:12 pmRNSEmployee Benefit Trust (“EBT”)
7th Apr 20264:45 pmRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSAppointment of Barclays as joint corporate broker
1st Apr 20267:00 amRNSDisposal of Horseferry House SW1
31st Mar 20264:45 pmRNSTotal Voting Rights
27th Mar 202612:45 pmRNSDirector/PDMR Shareholding
24th Mar 202610:30 amRNSDirector/PDMR Shareholding
20th Mar 20264:15 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSNetwork building fully pre-let
16th Mar 20267:00 amRNSNetwork building fully pre-let
27th Feb 20264:45 pmRNSTotal Voting Rights
26th Feb 20267:32 amRNSDerwent London plc Disposal of 90 Whitfield Street
26th Feb 20267:00 amRNSResults for the Year Ended 31 December 2025
6th Feb 20264:40 pmRNSHolding(s) in Company
6th Feb 20267:00 amRNSDisposal of 80-85 Tottenham Court Road W1
30th Jan 20264:45 pmRNSTotal Voting Rights
22nd Jan 20269:00 amRNSDirectorate change
15th Jan 202611:00 amRNSHolding(s) in Company
31st Dec 20251:15 pmRNSTotal Voting Rights
31st Dec 20251:15 pmRNSTotal Voting Rights
17th Dec 20257:00 amRNSPlanning success at Blue Star House SW9
9th Dec 20257:00 amRNSBurberry extends commitment to Horseferry House
28th Nov 20254:45 pmRNSTotal Voting Rights
6th Nov 20257:00 amRNSThird Quarter Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.